US 11071780
Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 11071780 (Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K38/179, A61K39/3955